# Methotrexate Preservative Free (methotrexate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/methotrexate

> Methotrexate Preservative Free (methotrexate), sponsored by PFIZER INC (PFE), received a complete response letter from the FDA; the decision is dated Jun 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Methotrexate Preservative Free (methotrexate) |
| Codes | ADX-2191 |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | [primary vitreoretinal lymphoma](https://sec-api.dev/indications/primary-vitreoretinal-lymphoma) |
| Modality |  |
| FDA designations | fast track, orphan, priority review |

## Timeline

### March 29, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA011719 SUPPL-131 (Efficacy): submission_status AP, submission_status_date 20210329, review_priority STANDARD; sponsor_name HOSPIRA; product METHOTREXATE PRESERVATIVE FREE (METHOTREXATE SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA011719%22

### Dec 2022: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-06-26, last confirmed 2025-06-26.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-058035): "Based on a pre-New Drug Application (NDA) meeting with the FDA in December 2022, Aldeyra submitted a literature-based NDA of ADX-2191 for the treatment of PVRL, which was accepted for Priority Review in March 2023." https://www.sec.gov/Archives/edgar/data/1341235/000121390025058035/ea024700001ex99-1_aldeyra.htm

### Jun 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month. Indication: primary vitreoretinal lymphoma.
- First seen 2025-02-28, last confirmed 2026-11-09.
- SEC Form 8-K (accession 0001193125-26-453537): "In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations." https://www.sec.gov/Archives/edgar/data/1341235/000119312526453537/aldx-20261109.htm
- SEC Form 10-Q (accession 0001193125-26-449742): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm
- SEC Form 10-Q (accession 0001341235-26-000010): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000010/aldx-20260630.htm
- SEC Form 10-Q (accession 0001341235-26-000006): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000134123526000006/aldx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-083012): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-266989): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000119312525266989/aldx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104971): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025104971/aldx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071602): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-030102): "For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter)." https://www.sec.gov/Archives/edgar/data/1341235/000095017025030102/aldx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-058035): "In June 2023, Aldeyra received a Complete Response Letter that stated that the available literature was not sufficient to demonstrate efficacy and that adequate and well-controlled trials were required for approval." https://www.sec.gov/Archives/edgar/data/1341235/000121390025058035/ea024700001ex99-1_aldeyra.htm

### 1H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2/3.
- First seen 2026-02-27, last confirmed 2026-02-27.
- SEC Form 10-K (accession 0001193125-26-083012): "Based on feedback from the FDA, we plan to initiate a Phase 2/3 clinical trial of ADX-2191 in retinitis pigmentosa in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2026-02-27, last confirmed 2026-02-27.
- SEC Form 10-K (accession 0001193125-26-083012): "Top-line results from the clinical trial are expected in 2026." https://www.sec.gov/Archives/edgar/data/1341235/000119312526083012/aldx-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/methotrexate.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Methotrexate Preservative Free (methotrexate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/methotrexate

```bibtex
@misc{secapidev_pdufa_methotrexate_20261116,
  title        = {Methotrexate Preservative Free (methotrexate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/methotrexate}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_methotrexate_20261116","title":"Methotrexate Preservative Free (methotrexate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/methotrexate","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
